Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicsight partners Toshiba for Japan focus

This article was originally published in Clinica

Executive Summary

Computer-aided design (CAD) specialist Medicsight and Toshiba Medical Systems have signed a preliminary commercial agreement to make the former's MedicRead Colon and ColonCAD software available in Japan. Financials details of the collaboration were not disclosed, but London, UK-based Medicsight did say that the two companies would work towards MHLW (Ministry of Health, Labour and Welfare) approval of the technology through Toshiba's system integration subsidiary. The MedicRead Colon and ColonCAD software are designed to aid radiologists in the identification of colorectal polyps and tumours during early stages, thus enhancing the chance of successful treatment. Medicsight and Toshiba have an established relationship in the field of virtual colonoscopy, as both firms are also working together in an initiative to help radiologists and gastroenterologists use software to interpret virtual colonoscopy/CT colonography images for more detailed evaluation. Medicsight said that this initiative will also continue through 2008 and beyond.

You may also be interested in...



Sandoz Launches US Awareness Campaign

Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.

EU Plans IP Law Shake-Up

European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.

Molecular Dx Company Biocartis ‘At Inflection Point’ As It Eyes Infectious Disease Market

Belgian developer of cancer diagnostics is building an infectious disease portfolio on the back of its new SARS-CoV-2 test and collaborations with Immunexpress and Endpoint Health.

Topics

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel